[
    [
        {
            "time": "",
            "original_text": "【浙商医药|深度】服务延伸+投资孵化，药筛公司突破CXO天花板——从维亚生物看研发产业链早期公司商业模式",
            "features": {
                "keywords": [
                    "浙商医药",
                    "服务延伸",
                    "投资孵化",
                    "药筛公司",
                    "CXO",
                    "维亚生物",
                    "研发产业链",
                    "商业模式"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "【浙商医药|深度】服务延伸+投资孵化，药筛公司突破CXO天花板——从维亚生物看研发产业链早期公司商业模式",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]